Several trials are investigating the safety and feasibility of different combinations with or without ALK-I using several classes of drug: chemotherapy, antiangiogenesis (bevacizumab), small molecule multi-TKI (lenvatinib, crizotinib, apatinib) or selective inhibitors (anti-MEK, anti-MET, or anti-SHP-2), immune checkpoint inhibitors (pembrolizumab, atezolizumab, camrelizumab, IBI-322, IBI-318), and novel immunomodulators (autologous tumor-infiltrating lymphocytes, dendritic cell vaccines, anti-CD20, natural killer cells) (Table 5) [99]. This evidence concerns the gene MAP2K7 and neoplasm.